Evidence map›Paper›PMID 38234425›Full record

ArticleFrontiers in endocrinology2023

Systemic effects of hypophosphatasia characterization of two novel variants in the

Luis Martínez-Heredia, Manuel Muñoz-Torres, Raquel Sanabria-de la Torre, Ángela Jiménez-Ortas, Francisco Andújar-Vera, Trinidad González-Cejudo, Victoria Contreras-Bolívar, Sheila González-Salvatierra, José María Gómez-Vida, Cristina García-Fontana and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Luis Martínez-HerediaInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
Manuel Muñoz-TorresInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
Raquel Sanabria-de la TorreInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
Ángela Jiménez-OrtasInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
Francisco Andújar-VeraDepartment of Computer Science and Artificial Intelligence, University of Granada, Granada, Spain.
Trinidad González-CejudoInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
Victoria Contreras-BolívarEndocrinology and Nutrition Unit, University Hospital Clínico San Cecilio, Granada, Spain.
Sheila González-SalvatierraInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
José María Gómez-VidaPediatric Unit, University Hospital Clínico San Cecilio, Granada, Spain.
Cristina García-FontanaInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
Beatriz García-FontanaInstituto de Investigación Biosanitaria de Granada, Granada, Spain.
Instituto de Investigación Biosanitaria de Granada · ESUniversidad de Granada · ESInstituto Andaluz de Ciencias de la Tierra · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hypophosphatasia (HPP) is an inborn metabolic error caused by mutations in the ALPL gene encoding tissue non-specific alkaline phosphatase (TNSALP) and leading to decreased alkaline phosphatase (ALP) activity. Although the main characteristic of this disease is bone involvement, it presents a great genetic and clinical variability, which makes it a systemic disease. Methods: Patients were recruited based on biochemical assessments. Diagnosis was made by measuring serum ALP and pyridoxal 5-phosphate levels and finally by Sanger sequencing of the ALPL gene from peripheral blood mononuclear cells. Characterization of the new variants was performed by transfection of the variants into HEK293T cells, where ALP activity and cellular localization were measured by flow cytometry. The dominant negative effect was analyzed by co-transfection of each variant with the wild-type gene, measuring ALP activity and analyzing cellular localization by flow cytometry. Results: Two previously undescribed variants were found in the ALPL gene: leucine 6 to serine missense mutation (c.17T>C, L6S) affecting the signal peptide and threonine 167 deletion (c.498_500delCAC, T167del) affecting the vicinity of the active site. These mutations lead mainly to non-pathognomonic symptoms of HPP. Structural prediction and modeling tools indicated the affected residues as critical residues with important roles in protein structure and function. In vitro results demonstrated low TNSALP activity and a dominant negative effect in both mutations. The results of the characterization of these variants suggest that the pleiotropic role of TNSALP could be involved in the systemic effects observed in these patients highlighting digestive and autoimmune disorders associated with TNSALP dysfunction. Conclusions: The two new mutations have been classified as pathogenic. At the clinical level, this study suggests that both mutations not only lead to pathognomonic symptoms of the disease, but may also play a role at the systemic level.

Indexed as

HypophosphatasiaAlkaline PhosphataseHEK293 CellsHumansLeukocytes, MononuclearMutationAlkaline PhosphataseALPL protein, humanautoimmune diseasesgastrointestinal disordershypophosphatasiametabolic diseasetissue non-specific alkaline phosphatase

Identifiers

PMID38234425
PMCPMC10792043
OpenAlexW4390541742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.